Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: A study of gene expression in the DBCG82bc cohort

Clinical Cancer Research

Volumn 20, Issue 20, 2014, Pages 5272-5280

  Tramm, Trine ^a   Mohammed, Hayat ^b   Myhre, Simen ^b,c,d   Kyndi, Marianne ^a   Alsner, Jan ^a   Børresen Dale, Anne Lise ^b,c   Sørlie, Therese ^b,c   Frigessi, Arnoldo ^b   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Atlantis Medical University College   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; FORMALDEHYDE; METHOTREXATE; PARAFFIN; TAMOXIFEN; TRANSCRIPTOME;

ADH1B GENE; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; COHORT ANALYSIS; DNALI1 GENE; EMBEDDING; FEMALE; FROZEN SECTION; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IGKC GENE; INDIVIDUALIZATION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; PATIENT CARE; PREDICTION; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RGS1 GENE; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME; ADJUVANT THERAPY; BREAST NEOPLASMS; CANCER GRADING; GENETICS; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REPRODUCIBILITY; RISK FACTOR; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84909619045     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0458     Document Type: Article

References (49)

1. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-106.
2. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
3. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c Randomised Trial. Lancet 1999;353:1641-8.
4. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116-26.
5. EBCTCG. Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127-35.
6. The National Institutes Of Health Consensus Development Conference: adjuvant therapy for breast cancer. Bethesda, Maryland, USA. November 1-3, 2000. Proceedings. J Natl Cancer Inst Monogr 2001:1-152.
7. Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol 2001;19:1539-69.
8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22:1736-47.
9. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
10. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
11. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
12. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
13. Perou CM, Sørlie T, Eisen MB, vande Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
14. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 2005;365:671-9.
15. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008;26:1419-26.
16. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247-53.
17. Grantzau T, Mellemkjaer L, Overgaard J. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother Oncol 2013;106:42-9.
18. McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011;100:167-75.
19. Højris I, Andersen J, Overgaard M, Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol 2000;39:355-72.
20. Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999;354:1425-30.
21. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Locoregional recurrence after mastectomy in high-risk breast cancer-risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol 2006;79:147-55.
22. Danish Breast Cancer Cooperative Group, Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:2268-75.
23. Overgaard M, Christensen JJ. Postoperative radiotherapy in DBCG during 30 years. techniques, indications and clinical radiobiological experience. Acta Oncol 2008;47:639-53.
24. Myhre S, Mohammed H, Tramm T, Alsner J, Finak G, Park M, et al. In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome. PLoS One 2010;5:e14002.
25. Tibshirani R. Regression shrinkage and selection via lasso. J Royal Stat Soc 1996;58:267.
26. Tramm T, Sørensen BS, Overgaard J, Alsner J. Optimal reference genes for normalization of qRT-PCR data from archival formalin-fixed, paraffin-embedded breast tumors controlling for tumor cell content and decay of mRNA. Diagn Mol Pathol 2013;22:181-7.
27. Tramm T, Hennig G, Kyndi M, Alsner J, Sørensen FB, Myhre S, et al. Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptormRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. Virchows Arch 2013;463:775-86.
28. Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J, et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012;102:122-9.
29. Müller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, et al. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue - a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 2011;20:1-10.
30. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, et al. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 2008;47:591-9.
31. Andersen J, Bentzen SM, Poulsen HS. Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. Eur J Cancer Clin Oncol 1988;24:377-84.
32. R Development Core Team. R: A Language and Environment for StatisticalComputing.RFoundation for Statistical Computing. Vienna, Austria; 2011.
33. Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006;8:R62.
34. Niméus-Malmström E, Krogh M, Malmstrom P, Strand C, Fredriksson I, Karlsson P, et al. Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Res 2008;10:R34.
35. Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009;15:4181-90.
36. Sabatier R, Finetti P, Cervera N, Tallet A, Benchalal M, Houvenaeghel G, et al. Gene expression profiling and its utility in prediction of local relapse after breast-conserving therapy in early breast cancer. Cancer Genomics Proteomics 2011;8:199-209.
37. Cheng SH, Horng CF, West M, Huang E, Pittman J, Tsou MH, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006;24:4594-602.
38. Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005;65:7169-76.
39. Eschrich SA, Fulp WJ, Pawitan Y, Foekens JA, Smid M, Martens JW, et al. Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res 2012;18:5134-43.
40. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
41. Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, et al. Search for a gene expression signature of breast cancer local recurrence in young women. Clin Cancer Res 2012;18:1704-15.
42. Tramm T, Kyndi M, Myhre S, Nord S, Alsner J, Sørensen F, et al. Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of locoregional control and benefit from post-mastectomy radiotherapy in high risk breast cancer patients. Acta Oncol 2014 Jun 24. [Epub ahead of print].
43. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappaCas acompatible prognostic marker in human solid tumors. Clin Cancer Res 2012;18:2695-703.
44. Chen Z, Gerhold-Ay A, Gebhard S, Boehm D, Solbach C, Lebrecht A, et al. Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One 2012;7:e44741.
45. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, et al. The prognostic relevance of tumour-in filtrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 2013;333:222-8.
46. Rangel J, Nosrati M, Leong SP, Haqq C, Miller JR3rd, Sagebiel RW, et al. Novel role for RGS1 in melanoma progression. Am J Surg Pathol 2008;32:1207-12.
47. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, et al. A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 2009;15:6987-92.
48. Piovan E, Tosello V, Indraccolo S, Masiero M, Persano L, Esposito G, et al. Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis. Cancer Res 2007;67:8605-14.
49. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012;9:e1001216.